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radiation-resistant cell line, and to investigate the mechanism underly-
ing the radioresistancy in non small cell lung cancer cells.
Methods: A human NSCLC cell line, H460, was irradiated with x-rays 
to an accumulated dose of 40 Gy over 10 weeks to produce the radia-
tion-resistant cell line. To characterize the radiation-resistant cells, we 
checked the morphological features, clonogenicity, radiosensitivity, cell 
growth kinetics, and the levels for several candidate proteins.
Results: We established the radiation-resistant cell line and named as 
H460R. Clonogenic assay and MTT assay clearly showed that H460R 
cells were radioresistance as compared with mother H460 cells. FACS 
analysis revealed that x-ray did not induce the apoptosis in H460R 
cells, while many of H460 cells died. Consistent with, x-ray induced 
the cleavage of PARP, an indicator for apoptotic cell death, in H460 
cells, but not in H460R cells. To ﬁnd the putative upstream regulators 
for radiation-induced apoptosis, we focused on the PKC superfamily 
proteins, and found that x-ray markedly induced PKCδ activation in 
radio-sensitive H460 cells, but not in radio-resistant H460R cells. 
Conclusions: These results indicate that radioresistance of NSCLC cell 
is possibly mediated by a mechanism dependent on PKCδ, suggesting 
that the combined therapy of x-ray and PKCδ activators may improve 
the efﬁcacy of cancer treatment. 
P2-113 BSTB: Radiation Biology Posters, Tue, Sept 4 
High-LET radiation activate apoptotic signaling through Bak/Bax 
and JNK in low-LET radiation resistant NSCLC cells 
Viktorsson, Kristina1 Ståhl, Sara1 Radulescu, Ada-Irina2 Mörk, Birgitta1 
Stenerlöw, Bo3 Lewensohn, Rolf1 
1 Karolinska Biomics Center, Dep. Oncology/pathology, Karolinska 
Institutet and University Hospital, Stockholm, Sweden 2 Karolinska 
Biomics Center, Dep. Oncology/pathology, Karolinska Institutet and 
University Hospitalt, Stockholm, Sweden 3 Biomedical Radiation Sci-
ences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden 
Background: Future radiotherapy for cancer treatment will likely al-
low the use of different radiation qualities including high LET acceler-
ated ions. In order to select for tumours which efﬁciently can be treated 
with high LET radiotherapy, there is a need to characterize which 
signalling pathways that is of importance for accelerated ion therapy. In 
the present study we compared apoptotic signalling in response to low 
and high LET radiation in NSCLC cells. 
Methods: NSCLC cells have been irradiated with either high LET 
accelerated nitrogen or low LET photons and apoptotic signalling 
parameters (caspase-3 activation, mitochondrial depolarization, Bcl-2 
family protein activation, Mitogen activated protein kinase (MAPK) 
activation) have been examined at various times post irradiation using 
a combination of ﬂow cytometry, western blotting and immunoﬂures-
cence microscopy analysis. 
Results and Conclusion: We found that high LET radiation can trig-
ger apoptotic signalling in low LET radiation resistant NSCLC cells. 
Importantly, we show for the ﬁrst time that apoptotic signalling in re-
sponse to accelerated nitrogen ions includes activation of Bak and Bax, 
depolarization of mitochondria and release of cytochrome c, activa-
tion of caspase-3/7 and induction of apoptotic morphology. Moreover, 
our data suggest that signalling by the MAPK JNK is of importance 
for apoptotic propensity after exposure to accelerated nitrogen ions. 
Importantly, as the NSCLC cells used in the present study neither show 
Bak/Bax nor JNK activation after exposure to low LET γIR but do so 
after irradiation with high LET accelerated nitrogen ions, our results 
suggest that low and high LET radiation utilizes different signalling 
pathways from the DNA damage to Bak/Bax and JNK activation. 
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We have found that human lung cancer tumors and experimental mouse 
tumors develop unique angiogenic phenotypes characterized by pre-
dominant expression of one family of angiogenic factors over another. 
Our previous data suggest that in lung cancer, angiogenic CXC chemo-
kines account for a signiﬁcant degree of the variability in angiogenesis 
between tumors (as measured by vessel density staining). On the other 
hand, while VEGF expression was not associated strongly with the vas-
cularity of the tumor, it remained a poor prognostic factor. Mizukami 
et al recently showed that in cells unable to express VEGF in response 
to hypoxia, K-ras mutations favored the expression of the angiogenic 
CXC chemokine CXCL8, through NADPH-oxidase (NOX) mediated 
generation of H2O2 and activation of NFκB. This is highly relevant to 
our study of human and mouse lung tumors, in which K-ras mutations 
are quite common. In this study we examined the expression of angio-
genic CXC chemokines by cell lines with mutant or wild type K-ras. 
Mutant K-ras cell lines expressed higher levels of angiogenic CXC 
chemokines compared with wild type K-ras cell lines. This increase in 
CXC chemokine expression was inhibited by pharmacologic inhibitors 
of NADPH-oxidase (NOX) enzymes in K-ras mutant, but not wild type 
cell lines. We also screened 90 human NSCLC tumor specimens for the 
presence of mutations in codon 12 of K-ras. In 23 tumors with mutant 
K-ras, the levels of angiogenic CXC chemokines (103±52 ng/mg) was 
signiﬁcantly higher than in 67 tumors with wild type codon 12 (24±6 
ng/mg. p=0.014). In contrast, the levels of VEGF were not statisti-
cally signiﬁcantly different, but mutant K-ras was associated with at 
trend toward lower levels of (28±7 ng/mg in wild type vs 12±3 ng/.
mg in mutant tumors. p=0.06). Our data suggest a connection between 
a common mutation in lung cancer, and the induction of NOX-depen-
dent H2O2 expression, which in turn promotes the expression of the 
angiogenic CXC chemokines. This is one of several potential pathways 
by which CXC chemokines can be over expressed in lung cancer. Addi-
tionally, our data point out the importance of recognizing the diversity 
of angiogenic phenotypes in cancer, which must be accounted for in 
designing targeted anti-angiogenic therapy. 
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Background: In lung adenocarcinomas, the Ras signaling pathway 
is often constitutively activated, and K-Ras activating mutations are 
widespread. Given the failure in clinical trials of compounds that target 
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the biological activity of the Ras proteins, the key molecular path-
ways downstream of K-Ras involved in promoting lung tumorigenesis 
need to be identiﬁed in order to provide better targets for lung cancer 
therapy. We hypothesize that a crucial target of oncogenic K-Ras in the 
lung is nuclear factor kappa B (NFκB). NFκB is a dimeric transcription 
factor that promotes proliferation, mediates resistance to apoptosis, and 
is abnormally activated in a large variety of human malignancies. 
Methods: In order to analyze the role of NFκB downstream of K-Ras 
in the airway epithelium, a tetracycline-inducible system was used 
to stably and inducibly express either the wild type form of K-Ras 
(K-RasWT) or the oncogenic form (K-RasV12) in the lung adenocarci-
noma H1703 cell line. We also analyzed primary human bronchial cells 
that were either immortalized (AALEB) or immortalized and trans-
formed with K-RasV12 (AALEB-K-Ras). NFκB activity in these cells 
was analyzed by western blotting, eletrophoretic mobility shift assays, 
luciferase assays and expression of NFκB target genes by real-time 
PCR. 
Results: Expression of K-Ras-WT or K-RasV12 in H1703 cells after 
tetracycline induction was accompanied by both increased expression 
of NFκB target genes, and increased NFκB DNA binding activity. 
DNA binding was mediated primarily by p50 and p65 NFκB subunits. 
Although NFκB luciferase reporter activity was detectable prior to K-
Ras expression, expression of K-RasV12, but not K-Ras-WT, enhanced 
NFκB activity. Interestingly, K-RasV12 does not activate NFκB by the 
canonical NFκB activation pathway; in both H1703 and AALEB cells 
expressing K-RasV12, there was no increase in IkappaBalpha (IκBα) 
phosphorylation/degradation. Nonetheless, activation seems to be 
dependent on IkappaB kinase (IKK) activity for the following reasons: 
(1) When compared to AALEB cells, AALEB K-Ras cells displayed 
increased IKK phosphorylation levels; and (2) speciﬁc inhibition of 
IKKβ activity in H1703 cells by the novel pyridine derivative com-
pound 65-1942 (obtained under MTA agreement with Bayer) sup-
pressed NFκB activity. Finally, as no increase in p65 phosphorylation 
at S536 was observed in either cell type expressing K-RasV12, the 
mechanism of NFκB activation does not involve direct phosphorylation 
of p65 at S536 by IKK. 
Conclusions: We have determined a causal link between K-RasV12 
expression and NFκB activation in lung epithelial cells in vitro. NFκB 
in these cells is not activated either by the canonical pathway of IκBα 
phosphorylation/degradation or by p65 phosphorylation at S536. Al-
though the speciﬁc mechanism of activation is being investigated both 
in H1703 and in primary AALEB cells, we have shown that it depends 
on IKK. IKKβ inhibitors, therefore, represent a potentially promising 
new therapeutic direction in lung cancer. Studies are underway to con-
ﬁrm their efﬁcacy in a pre-clinical lung cancer mouse model.
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Background: Geﬁtinib, a selective tyrosine kinase inhibitor (TKI) of 
epidermal growth factor receptor (EGFR), may inhibit functions of 
ATP-binding cassette (ABC) transporters by competing against the ATP 
binding sites. The aim of this study is to investigate the combination 
effects of geﬁtinib plus four commomly used chemotherapeutic agents 
for the treatment of non-small cell lung cancer (NSCLC) in a geﬁtinib-
insensitive lung cancer cell line and its adriamycin-induced multi-drug 
resistant subclones. 
Methods: NCI-H23 was a lung adenocarcinoma cell line with wide 
type EGFR gene expression. Its high P-glycoprotein (Pgp) expression 
subclones H23 adr 0.1 and H23 adr 0.3 were developed by stepwise 
exposure to escalating concentrations of adriamycin. The expression 
levels of (Pgp), breast cancer resistant protein (BCRP), and mutidrug 
resistant protein-1 (MRP-1) were checked by RT-QPCR and immunob-
lot. The combination effects of geﬁtinib plus single chemotherapeutic 
agents including paclitaxel (Pac), docetaxel (Doc), vinorelbine (NVB) 
and gemcitabine (Gem) were evaluated by using the tetrazolium dye 
colormetric assay with application of the classical isobole methods in 
these cell lines. To evaluate the inhibition of ABC transporters-medi-
ated drugs efﬂux, Rhodamine 6G was used as the ﬂuorescence probe 
for evaluating the inhibitory effects of geﬁtinib (0-10 μM) on the ABC 
transporters. 
Results: We found that H23 Pgp subclones showed increased resis-
tance to three antitubulins, Pac, Doc and NVB, but not to Gem and ge-
ﬁtinib. Geﬁtinib could partially reverse Pgp related Pac, Doc and NVB 
resistance in a dose-dependent fashion, showing marked synergistic ef-
fects, while geﬁtinib showed an additive combination effect with Gem. 
There was no statistical difference in the values of combination index 
between geﬁtinib plus each antitubulins. Rhodamine 6G-efﬂux assay in 
the tested cell lines revealed that ﬂuorescence-efﬂux was inhibited with 
ﬂuorescence accumulation by geﬁtinib in a dose-dependent fashion. 
Conclusions: Our results showed that geﬁtinib could enhance cytotox-
icities of anti-tubulines in Pgp expressing NSCLC cells which showed 
wild type EGFR. Our results provide a rationale to test these combina-
tions as salvage treatment in NSCLC patients who failed prior antitubu-
lin treatment and also in patients whose tumors express high Pgp.
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Animal studies demonstrated that females are more susceptible than 
males to benzo[a]pyrene (BaP)-induced toxicities, including lung car-
cinogenesis. Elevation of cyclooxygenase-2 (COX-2) ex-pression has 
been shown to increase the risk of cancer development. BaP induces 
COX-2 expression, and an interaction between BaP and estrogen in 
relation to COX-2 expression is suspected. In the present study, 10 
mMBaP alone only slightly increased COX-2 mRNA expression and 
10 nM 17-beta estradiol (E2) alone slightly increased prostaglandin 
E2 (PGE2) secretion in human bronchial epithelial cells. However, 
co-treatment with BaP and E2 potentiated COX-2 mRNA expression 
and signiﬁcantly elevated PGE2 secretion. Utilizing speciﬁc inhibitors 
and reporter assays, we further investigated the potentiation mecha-
nisms of E2 on BaP-induced COX-2 expression. First, E2 activated 
estrogen receptor to increase PGE2 secretion, which directly increased 
